Stock MEIP MEI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.05 USD -1.61% Intraday chart for MEI Pharma, Inc. -6.15% -47.41%
Apr. 11 MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data CI
Apr. 11 MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 178.2 437.8 320.9 80.56 43.84 20.32 - -
Enterprise Value (EV) 1 178.2 425.4 320.9 80.56 43.84 20.32 20.32 20.32
P/E ratio -10.4 x -8.1 x -6.33 x -1.38 x -1.38 x 0.93 x -0.52 x -0.86 x
Yield - - - - - - - -
Capitalization / Revenue 36.3 x 15.1 x 12.6 x 1.98 x 0.9 x 0.31 x 3.25 x 0.81 x
EV / Revenue 36.3 x 15.1 x 12.6 x 1.98 x 0.9 x 0.31 x 3.25 x 0.81 x
EV / EBITDA - - - - - - - -
EV / FCF -6,013,028 x 13,121,162 x -9,821,453 x -1,636,506 x - - - -
FCF Yield -0% 0% -0% -0% - - - -
Price to Book - - 7.76 x - - - - -
Nbr of stocks (in thousands) 3,565 5,300 5,630 6,658 6,663 6,663 - -
Reference price 2 50.00 82.60 57.00 12.10 6.580 3.050 3.050 3.050
Announcement Date 8/28/19 9/9/20 9/2/21 9/8/22 9/26/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4.915 28.91 25.54 40.7 48.82 65.38 6.25 25
EBITDA - - - - - - - -
EBIT 1 -46.24 -24.54 -69.68 -75.48 -36.76 20.87 -42.32 -28.34
Operating Margin -940.9% -84.88% -272.9% -185.48% -75.31% 31.92% -677.1% -113.36%
Earnings before Tax (EBT) 1 -16.82 -46.02 -50.57 -54.45 -31.84 24.41 -41.28 -24.83
Net income 1 -16.82 -46.02 -50.58 -54.45 -31.84 24.41 -41.28 -24.83
Net margin -342.2% -159.15% -198.06% -133.8% -65.22% 37.33% -660.48% -99.31%
EPS 2 -4.800 -10.20 -9.000 -8.800 -4.780 3.285 -5.850 -3.550
Free Cash Flow -29.64 33.36 -32.67 -49.22 - - - -
FCF margin -603.05% 115.39% -127.95% -120.95% - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/28/19 9/9/20 9/2/21 9/8/22 9/26/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 13.39 18.22 9.694 11.41 8.73 32.74 5.894 1.457 65.3 - 0.025 0.0333 - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -14.48 -11.24 -21.56 -16.2 -18.22 8.926 -16.39 -11.08 55.28 -11.93 -11.49 -12.23 -14.2 -14.9
Operating Margin -108.13% -61.66% -222.38% -141.9% -208.69% 27.27% -278.1% -760.47% 84.66% - -45,970.68% -36,682.66% - -
Earnings before Tax (EBT) 1 -11.88 -5.766 -8.725 -16.06 -16.62 10.25 -15.44 -10.03 56.37 -11.06 -10.74 -11.49 -13.6 -14.3
Net income 1 -11.88 -5.766 -8.725 -16.06 -16.62 10.25 -15.44 -10.03 56.37 -11.06 -9.942 -10.63 -10.9 -11.5
Net margin -88.74% -31.64% -90% -140.73% -190.42% 31.32% -261.93% -688.33% 86.33% - -39,769.32% -31,880.2% - -
EPS 2 -2.200 -1.000 -1.400 -2.400 -2.400 1.600 -2.320 -1.507 8.460 -1.660 -1.487 -1.580 -1.640 -1.720
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/10/21 2/10/22 5/23/22 9/8/22 11/14/22 2/9/23 5/11/23 9/26/23 11/9/23 2/13/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 12.3 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -29.6 33.4 -32.7 -49.2 - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - -26.4% - -22.4% - - -
Assets 1 - - 191.9 - 142.2 - - -
Book Value Per Share - - 7.350 - - - - -
Cash Flow per Share - - - - -7.880 - - -
Capex 0.22 0.89 0.71 0.48 - - - -
Capex / Sales 4.42% 3.09% 2.77% 1.18% - - - -
Announcement Date 8/28/19 9/9/20 9/2/21 9/8/22 9/26/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for MEI Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.05 USD
Average target price
23 USD
Spread / Average Target
+654.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MEI PHARMA, INC. Stock MEI Pharma, Inc.
-47.41% 20.32M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MEIP Stock
  4. Financials MEI Pharma, Inc.